Advertisement

Current Diabetes Reports

, 18:138 | Cite as

Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes

  • Ilaria Cavallari
  • Alessia Delli Veneri
  • Ernesto Maddaloni
  • Rosetta Melfi
  • Giuseppe Patti
  • Nicola Napoli
  • Paolo Pozzilli
  • Germano Di Sciascio
Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)
  • 177 Downloads
Part of the following topical collections:
  1. Topical Collection on Macrovascular Complications in Diabetes

Abstract

Purpose of the Review

To summarize available evidence regarding lipid-lowering interventions for the prevention of cardiovascular disease in patients with diabetes.

Recent Findings

Statins and non-statin therapies that act through upregulation of LDL receptor expression are associated with similar cardiovascular risk reduction per decrease in LDL cholesterol.

Summary

In subjects with diabetes, with or without established cardiovascular disease, each 39 mg/dl reduction in LDL cholesterol observed with statins is associated with a 21% relative reduction in the risk of major coronary events at 5 years. Statins remain the first-line lipid-lowering agents for the management of dyslipidemia in individuals with diabetes; however, the addition of non-statin therapies to lower LDL cholesterol, such as ezetimibe and PCSK-9 inhibitors, to maximally tolerated statin therapy is recommended in patients with atherosclerotic cardiovascular disease and baseline LDL cholesterol over 70 mg/dl. Recent data support even lower LDL cholesterol targets (< 55 mg/dl) to further reduce the risk of cardiovascular events especially in subjects with diabetes and documented cardiovascular disease.

Keywords

Diabetes Lipid-lowering interventions Cardiovascular disease 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ilaria Cavallari, Alessia Delli Veneri, Rosetta Melfi, Nicola Napoli, and Germano Di Sciascio declare that they have no conflict of interest.

Ernesto Maddaloni has received speaker fees from Merck-Serono and grant support from scientific societies through AstraZeneca and Lilly.

Giuseppe Patti is a speaker/consultant/advisory board member for Amgen, AstraZeneca, Bayer, BMS-Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Malesci, MSD, PIAM, Sanofi, and Sigma-Tau.

Paolo Pozzilli received research funds and consulting fees from Sanofi, Lilly, and Medtronic, AstraZeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    International Diabetes Federation. IDF Diabetes Atlas, 8th Edn, 2017. http://diabetesatlas.org/resources/2017-atlas.html. Accessed September 17, 2018.
  2. 2.
    Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100–7.CrossRefGoogle Scholar
  3. 3.
    Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765–75.CrossRefGoogle Scholar
  4. 4.
    Hermans MP, Valensi P, Ahn SA, Rousseau MF. [HDL-C/apoA-I]: a multivessel cardiometabolic risk marker in women with T2DM. Diabetes Metab Res Rev. 2018;34.Google Scholar
  5. 5.
    Maddaloni E, Pozzilli P. SMART diabetes: the way to go (safe and multifactorial approach to reduce the risk for therapy in diabetes). Endocrine. 2014;46:3–5.CrossRefGoogle Scholar
  6. 6.
    Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–8.CrossRefGoogle Scholar
  7. 7.
    American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S86–S104.CrossRefGoogle Scholar
  8. 8.
    Goff DC, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–73.CrossRefGoogle Scholar
  9. 9.
    Catapano AL, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.CrossRefGoogle Scholar
  10. 10.
    Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London, England). 2008;371:117–25.CrossRefGoogle Scholar
  11. 11.
    Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefGoogle Scholar
  12. 12.
    • Lloyd-Jones DM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-Statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force. J Am Coll Cardiol. 2017;70:1785–822 This document provides a focused update to help guide clinicians on decision making regarding the use of non-statin therapies in patients with clinical atherosclerotic cardiovascular disease with or without comorbidities. CrossRefGoogle Scholar
  13. 13.
    Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.CrossRefGoogle Scholar
  14. 14.
    Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28:1029–34.CrossRefGoogle Scholar
  15. 15.
    • Silverman MG, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–97. This study demonstrated that the use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C are associated with similar risk reductions of major major vascular events per change in LDL-cholesterol. CrossRefGoogle Scholar
  16. 16.
    Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.CrossRefGoogle Scholar
  17. 17.
    Puzziferri N, Roshek TB III, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312:934–42.CrossRefGoogle Scholar
  18. 18.
    Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, et al. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012;164:117–24.CrossRefGoogle Scholar
  19. 19.
    Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;e34:378.Google Scholar
  20. 20.
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, W Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet (London, England). 2004;364:685–96.CrossRefGoogle Scholar
  21. 21.
    Collins R, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (London, England). 2003;361:2005–16.CrossRefGoogle Scholar
  22. 22.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial - lipid lowering arm (ASCOT-LLA): a multicentre randomi. Drugs. 2004;64:43–60.CrossRefGoogle Scholar
  23. 23.
    Knopp RH, D’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.CrossRefGoogle Scholar
  24. 24.
    de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One. 2014;9:e111247.CrossRefGoogle Scholar
  25. 25.
    Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (London, England). 2010;375:735–42.CrossRefGoogle Scholar
  26. 26.
    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.Google Scholar
  27. 27.
    Pre-entry characteristics of participants in the Lipid Research Clinics’ Coronary Primary Prevention Trial. J Chronic Dis. 1983;36:467–79.Google Scholar
  28. 28.
    The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med. 1992;152:1399–410.Google Scholar
  29. 29.
    AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRefGoogle Scholar
  30. 30.
    HPS2-THRIVE Collaborative Group, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.CrossRefGoogle Scholar
  31. 31.
    Sudhop T, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943 LP–1948.CrossRefGoogle Scholar
  32. 32.
    Kosoglou T, Guillaume M, Sun S, Pember LJC, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis. 2001;2:38.CrossRefGoogle Scholar
  33. 33.
    Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27.Google Scholar
  34. 34.
    Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100:46–52.CrossRefGoogle Scholar
  35. 35.
    Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–94.CrossRefGoogle Scholar
  36. 36.
    Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol. 2008;2:19–24.CrossRefGoogle Scholar
  37. 37.
    Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59:50–6.CrossRefGoogle Scholar
  38. 38.
    Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: The multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495–507.  https://doi.org/10.1016/j.jacc.2015.05.065.CrossRefGoogle Scholar
  39. 39.
    Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRefGoogle Scholar
  40. 40.
    Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs. without diabetes: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–82.  https://doi.org/10.1161/CIRCULATIONAHA.117.030950.CrossRefGoogle Scholar
  41. 41.
    Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–61.CrossRefGoogle Scholar
  42. 42.
    Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–93.CrossRefGoogle Scholar
  43. 43.
    Field T. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.CrossRefGoogle Scholar
  44. 44.
    Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–5.  https://doi.org/10.2337/diacare.15.7.820.CrossRefGoogle Scholar
  45. 45.
    Rubins HB, Robins SJ, Collins D. The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572–5.CrossRefGoogle Scholar
  46. 46.
    Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. J Clin Lipidol. 2011;6:9–20.CrossRefGoogle Scholar
  47. 47.
    Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–36.CrossRefGoogle Scholar
  48. 48.
    Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors--the clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588–91.CrossRefGoogle Scholar
  49. 49.
    Giugliano RP, Pedersen TR, Park JG, de Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet (London, England). 2017;390:1962–71.CrossRefGoogle Scholar
  50. 50.
    Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2017;2:1385–91.CrossRefGoogle Scholar
  51. 51.
    Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, de Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–50.CrossRefGoogle Scholar
  52. 52.
    Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, del Prato S, Tinahones FJ, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781–92.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ilaria Cavallari
    • 1
  • Alessia Delli Veneri
    • 1
  • Ernesto Maddaloni
    • 2
  • Rosetta Melfi
    • 1
  • Giuseppe Patti
    • 1
  • Nicola Napoli
    • 2
  • Paolo Pozzilli
    • 2
  • Germano Di Sciascio
    • 1
  1. 1.Department of Cardiovascular ScienceCampus Bio-Medico University of RomeRomeItaly
  2. 2.Department of Medicine, Unit of Endocrinology and DiabetesCampus Bio-Medico UniversityRomeItaly

Personalised recommendations